This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Why Is Centene (CNC) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Brookdale Incurs Loss in Q4 Due to Higher Costs, Shares Up 6%
by Zacks Equity Research
BKD's Q4 results reflect escalating general and administrative costs, partly offset by improved occupancy rates. It projects 2025 adjusted EBITDA within $430-$445 million.
MD Gains 11% Since Q4 Earnings Release, Unveils '25 View
by Zacks Equity Research
Pediatrix Medical's fourth-quarter results reflect a declining overall expense level. It estimates 2025 net income to lie within $98.3-$112.9 million.
Should Invesco S&P 500 Pure Value ETF (RPV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RPV
Tenet Q4 Earnings Beat Estimates on Favorable Payer Mix
by Zacks Equity Research
THC expects net operating revenues between $20.6 billion and $21 billion in 2025.
Is Invesco S&P 500 Pure Value ETF (RPV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RPV
Humana Incurs Wider Y/Y Loss in Q4 on Decline in Membership
by Zacks Equity Research
HUM's fourth-quarter results suffer a blow due to a membership decline in Medicare stand-alone PDP, partly offset by a strong Primary Care business. It currently expects 2025 adjusted EPS to be around $16.25.
Encompass Health Q4 Earnings Beat on Strong Discharge Growth
by Zacks Equity Research
EHC expects adjusted EPS from continuing operations in the range of $4.67-$4.96 in 2025.
Ensign Group Shares Plunge 12% Despite Q4 Earnings Beat
by Zacks Equity Research
ENSG's fourth-quarter results gain on strong contribution from the Skilled Services unit, partly offset by the escalating cost of services. It estimates 2025 adjusted EPS to be within $6.16-$6.34.
Centene Q4 Earnings Beat Estimates on Membership Growth, 2025 View Up
by Zacks Equity Research
CNC now projects premium and service revenues of $158-$160 billion in 2025.
Centene (CNC) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Centene (CNC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Centene (CNC) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 63.27% and 4.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Unlocking Q4 Potential of Centene (CNC): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Centene (CNC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Cigna (CI) Lags Q4 Earnings Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of -15.20% and 3.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Centene's Q4 Earnings Navigate Through Rising Medical Costs?
by Zacks Equity Research
CNC's fourth-quarter earnings are likely to have benefited from growing Commercial business.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Centene (CNC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Centene Expands Care in Hawaii With a Residential Program
by Zacks Equity Research
CNC's 'Ohana Health Plan joins forces with Hope Services Hawaii to launch a residential program offering integrated clinical care for members facing homelessness and complex health needs.
Zacks Industry Outlook Highlights UnitedHealth, Humana and Centene
by Zacks Equity Research
UnitedHealth, Humana and Centene have been highlighted in this Industry Outlook article.
Zacks Investment Ideas feature highlights: FedEx, Casey's General Stores and Centene
by Zacks Equity Research
FedEx, Casey's General Stores and Centene have been highlighted in this Investment Ideas article.
Insiders are Buying These 3 Large Cap Stocks
by Derek Lewis
Investors can see insider buys as an overall net positive concerning the longer-term outlook. Recently, these three companies have seen their insiders get busy.
3 HMO Stocks Poised to Thrive Despite Industry Headwinds
by Debasmita Chatterjee
The Medical-HMO industry benefits from a growing customer base and contract wins. However, industry challenges like rising costs and workforce shortages remain a concern. UNH, HUM and CNC are likely to navigate industry storms.
Cigna Stock Plunges 18.7% in 3 Months: Should You Buy, Hold or Sell?
by Zacks Equity Research
Despite market challenges, CI's strong fundamentals and growth drivers make it worth holding for long-term investors looking to capitalize on future recovery opportunities.